Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.
Christopher R. Flowers, MD, MS, and colleagues shed light on recent updates in the treatment armamentarium for follicular lymphoma and highlight ongoing investigations of novel agents and combinations.
/PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton s tyrosine kinase.